Treatment with midostaurin and other FLT3 targeting inhibitors is associated with an increased risk of cardiovascular adverse events in patients who underwent allogeneic hematopoietic stem cell transplantation with FLT3-mutated AML

The addition of midostaurin to standard chemotherapy has improved survival in patients with FLT3 -mutated AML. However, the impact of midostaurin and other FLT3 inhibitors (FLT3i) on cardiovascular adverse events (CAEs) has not been studied in patients who underwent allogeneic hematopoietic stem cel...

Full description

Saved in:
Bibliographic Details
Published in:Annals of hematology 2023-10, Vol.102 (10), p.2903-2908
Main Authors: Cremer, Anjali, Enssle, Julius C., Pfaff, Saskia, Kouidri, Khouloud, Lang, Fabian, Brandts, Christian, Zeiher, Andreas, Cremer, Sebastian, Steffen, Björn, Serve, Hubert, Bug, Gesine
Format: Article
Language:English
Subjects:
Cancer therapies
Chemotherapy
Drug dosages
Hematology
Kinases
Leukemia
Medical prognosis
Medical research
Medicine
Medicine & Public Health
Mutation
Oncology
Original
Original Article
Patients
Stem cell transplantation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The addition of midostaurin to standard chemotherapy has improved survival in patients with FLT3 -mutated AML. However, the impact of midostaurin and other FLT3 inhibitors (FLT3i) on cardiovascular adverse events (CAEs) has not been studied in patients who underwent allogeneic hematopoietic stem cell transplantation in a real-world setting. We reviewed 132 patients with AML who were treated with intensive induction therapy and consecutive allogeneic stem cell transplantation at our institution (42 FLT3 -mutated AML and 90 with FLT3 wildtype). We identified treatment with midostaurin and/or FLT3i as an independent risk factor for CAEs not resulting in higher non-relapse mortality (NRM) or impaired overall survival (OS). Hence, close monitoring for CAEs is warranted for these patients.
ISSN:0939-5555
1432-0584
1432-0584
DOI:10.1007/s00277-023-05396-y